Finotab 10, 1 Strip

✔️ Dosage & Administration

The starting dose depends on the patient’s eGFR and serum potassium levels.

Recommended Initial Dose

• eGFR ≥60 mL/min/1.73 m²: 20 mg once daily
• eGFR ≥25 to <60 mL/min/1.73 m²: 10 mg once daily
• eGFR <25 mL/min/1.73 m²: Use is not recommended

The target maintenance dose is 20 mg once daily. Tablets may be taken with or without food.

For patients unable to swallow tablets whole, the tablet may be crushed and mixed with water or soft food before administration.

Monitoring & Dose Adjustment

Serum potassium should be checked 4 weeks after starting treatment and after any dose adjustment. Further dose changes should be guided by potassium levels and kidney function.

Pediatric Use

Safety and effectiveness in individuals below 18 years of age have not been established.

Geriatric Use

No significant differences in efficacy or safety were observed in elderly patients compared with younger adults, and no dosage adjustment is required.

Hepatic Impairment

Avoid use in severe hepatic impairment (Child-Pugh Class C). No dosage adjustment is generally required in mild to moderate hepatic impairment, though additional potassium monitoring may be needed in moderate impairment.

If a dose is missed, it should be taken as soon as remembered on the same day. If not possible, skip the missed dose and continue the next scheduled dose. Do not take double doses.

In case of overdose, discontinue treatment immediately. Hyperkalemia is the most likely complication and should be managed according to standard treatment protocols. Hemodialysis is unlikely to effectively remove Finotab due to its high plasma protein binding.

✔️ Pregnancy & Lactation

There is insufficient human data regarding Finerenone use during pregnancy. Animal studies suggest possible developmental toxicity at high exposures. Therefore, it should only be used if clearly necessary.

It is unknown whether Finerenone passes into human breast milk, though animal studies indicate transfer into milk may occur. Breastfeeding should be avoided during treatment and for at least one day after the final dose.

✔️ Drug Interactions

Strong CYP3A4 Inhibitors

Concurrent use with strong CYP3A4 inhibitors can significantly increase Finotab levels and is contraindicated. Avoid grapefruit and grapefruit juice during therapy.

Moderate or Weak CYP3A4 Inhibitors

These agents may increase Finotab exposure and the risk of side effects. Monitor serum potassium carefully and adjust dosage if necessary.

Strong or Moderate CYP3A4 Inducers

These medications may reduce Finotab effectiveness by lowering drug exposure. Their combined use should be avoided.

✔️ Finotab should not be used in:

• Patients receiving strong CYP3A4 inhibitors
• Patients with adrenal insufficiency

✔️ Side Effects

Common adverse reactions include:

• Hyperkalemia
• Low blood pressure (hypotension)
• Hyponatremia

✔️ Precautions & Warnings

Finotab may increase serum potassium levels, especially in patients with impaired kidney function or those taking medications that elevate potassium. Serum potassium and eGFR should be measured before starting therapy and monitored regularly throughout treatment.

More frequent monitoring may be required in high-risk patients or those using medications that interfere with potassium excretion.

✔️ Storage:

Store below 30°C in a dry place away from light and moisture. Keep out of the reach of children.